Precision Editing Without Double-Strand DNA Breaks
Early CRISPR-Cas9 therapeutics relied on creating double-strand breaks in genomic DNA, which triggered cellular repair mechanisms that often introduced unpredictable insertion/deletion (indel) errors and occasional chromosomal translocations.
The next-generation base editors utilize a catalytically impaired Cas nickase fused to a deaminase enzyme. Rather than severing the DNA backbone, the editor chemically converts a single cytidine to uridine (read as thymidine) or adenosine to inosine (read as guanosine), correcting pathogenic single-nucleotide mutations with surgical accuracy.
Clinical Trial Efficacy Benchmarks (Cohort N=64)
| Clinical Endpoint | Baseline Pre-Treatment | Day 90 Post-Infusion | Statistical Significance |
|---|---|---|---|
| Circulating Serum PCSK9 | 480 ng/mL | 18 ng/mL (-96%) | p < 0.0001 |
| LDL-Cholesterol Level | 215 mg/dL | 62 mg/dL (-71%) | p < 0.0001 |
| Off-Target Indel Rate | N/A | < 0.01% (LOD) | Below Assay Noise |